Luxembourg, 8 October 2020
Vivion signs 15,000 sqm contracts for German office asset
Vivion Investments S.á r.l. (‘Vivion’) is proud to announce the signing of two lease contracts for approx. 15,300 sqm with two governmental tenants in one of its office assets in Germany.
The first lease contract for approx. 13,500 sqm was signed for 15 years with the State of Lower Saxony and the second lease contract for approx. 1,800 sqm was signed for seven years with the medical assessment service of the Health Insurance Companies of Lower Saxony.
The annualized in-place rent for the asset increased with 37% and will deliver approx. EUR 25 million of contractual rental income. With these transactions, the property is almost fully let with a WAULT of 14 years.
Vivion is pleased to announce the completion of the transactions despite the Corona situation as these demonstrate the quality of the portfolio and Vivion’s asset management capabilities.
Contact for more Information
Daan Bras – Investor Relations
T +31 652 0900 26
daan.bras@vivion.eu
Disclaimers
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or country. The Notes have been offered and sold only outside the United States to non-U.S. persons in accordance with Regulation S. No offering of Notes has been or will be made in the United States. The issued Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail
client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”), (ii) a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II, or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (as amended or superseded). Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPS Regulation. In the United Kingdom, this communication is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial
Promotion Order”), (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations etc.”) of the Financial Promotion Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). This communication is directed only at relevant persons and must not be acted on or relied on by
persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. This press release may include projections and other “forward-looking” statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of the company about further events and financial performance. No assurances can be given that such events or performance will occur as projected and actual results may differ materially from these projections.